Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer et al. · Journal of Clinical Oncology · 2003 · 2.1K citations

Medicine, Gynecology, Oncology +17

A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

Andreas du Bois · JNCI Journal of the National Cancer Institute · 2003 · 1.1K citations · Full text

Medicine, Gynecology, Oncology +17

Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

P. Vasey, Gordon C. Jayson, Amanda Gordon et al. · JNCI Journal of the National Cancer Institute · 2004 · 638 citations · Full text

Medicine, Oncology, Pharmacology +16

Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer

Jan P. Neijt, Svend Aage Engelholm, Malgorzata Tuxen et al. · Journal of Clinical Oncology · 2000 · 443 citations

Medicine, Oncology, Pharmacology +17

Highly Specific Prediction of Antineoplastic Drug Resistance With an In Vitro Assay Using Suprapharmacologic Drug Exposures

David H. Kern, Larry M. Weisenthal · JNCI Journal of the National Cancer Institute · 1990 · 176 citations

Medicine, Pharmacology, Cancer Pharmacology +8